Prognostic Value of Biomarkers in RCC

Pembrolizumab also demonstrated a disease-free survival benefit vs placebo for patients with clear-cell renal cell carcinoma.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Mary-Ellen Taplin, MD, gives her advice on how to achieve work-life balance and make other career advancements in genitourinary cancer.

Santosh Rao, MD, discusses the formation of new guidelines informing the use of integrative oncology for patients with kidney cancer from the Society for Integrative Oncology.

Practices should not differentiate treatment options based on race for patients with metastatic renal cell carcinoma, according to Jasmeet Kaur, MD.

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.